Spatiotemporal trends in global burden of rheumatic heart disease and associated risk factors from 1990 to 2019

Zhang, Liang; Tong, Zhuang; Han, Ruizheng; Li, Kaixiang; Zhang, Xin; Yuan, Ruixia

doi:10.1016/j.ijcard.2023.04.060

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These shared challenges result in inadequate healthcare resources and limited technical support for RHD prevention. Furthermore, there exists a substantial disparity in the access to treatment options with favorable outcomes, particularly for advanced-stage RHD patients [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Temporal Trends and Burden of Rheumatic Heart Disease in South Asia: A Comprehensive Analysis of Three Decades from Global Burden of Disease Study

Naseeb,

Khan,

Aslam Soomro

et al. 2024

Global Heart

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Temporal Trends and Burden of Rheumatic Heart Disease in South Asia: A Comprehensive Analysis of Three Decades from Global Burden of Disease Study

Naseeb,

Khan,

Aslam Soomro

et al. 2024

Global Heart

View full text Add to dashboard Cite

“…Conversely, if the upper limit of the 95% CI of the EAPC estimate was less than 0, a decreasing trend was recognized. When the 95% CI included 0, the trend change was not statistically significant [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

The burden and trends of headache disorders among the population aged 15–39: a study from 1990 to 2019

Yuan,

Tong,

Xiang

et al. 2023

J Headache Pain

Self Cite

View full text Add to dashboard Cite

Background To analyze the global burden of headache disorders in adolescents and young adults (AYAs). Methods Data of headache disorders in the 15–39 age groups were extracted from GBD 2019. The age-standardized rates (ASRs) of incidence, prevalence, and years lived with disability (YLDs) rate were used to describe the burden. Estimated Annual Percentage Changes (EAPCs) were used to describe the trend from 1990 to 2019. Results In 2019, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized YLDs rate (ASYR) in AYAs were 42,473.18 (95% CI: 34,836.35, 50,858.30) per 100,000, 12,566.18 (95% CI: 8542.10, 16,915.68) per 100,000 and 790.32 (95% CI: 129.56, 1786.52) per 100,000, respectively. From 1990 to 2019, the ASRs showed increasing trends, with EAPCs of 0.04 (95% CI: 0.03, 0.06), 0.05 (95% CI: 0.03, 0.07), and 0.08 (95% CI: 0.07, 0.10). Migraine accounted for 91.54% of headache-related YLDs. The burdens in females were higher than those in males, especially for ASYR. This burden was greatest in the high sociodemographic index (SDI) super region. In the temporal trend of ASIR, 127 (62.25%) countries showed upward trends, mainly distributed in East Asia, Central Asia, West Africa, and Western Latin America. Conclusions The burden of headache disorders in the global population aged 15–39 is severe, especially among females and in countries with high SDI. Furthermore, this burden has been steadily increasing over the past three decades. Those findings assist in implementing targeted intervention measures.

show abstract

“…Rheumatic heart disease is a commonly acquired heart disease caused by an untreated or recurring GAS infection and is associated with high risks of morbidity, disability, and mortality [ 22 , 23 ]. A recent global burden of disease study estimated that approximately 33 million prevalent cases of rheumatic heart disease, leading to more than 9 million disability-adjusted life years lost and approximately 275,000 deaths each year [ 23 ].…”

Section: Burden Of Gas Infectionsmentioning

confidence: 99%

Recent Scientific Advancements towards a Vaccine against Group A Streptococcus

Fan,

Toth,

Stephenson

2024

Vaccines

View full text Add to dashboard Cite

Group A Streptococcus (GAS), or Streptococcus pyogenes, is a gram-positive bacterium that extensively colonises within the human host. GAS is responsible for causing a range of human infections, such as pharyngitis, impetigo, scarlet fever, septicemia, and necrotising fasciitis. GAS pathogens have the potential to elicit fatal autoimmune sequelae diseases (including rheumatic fever and rheumatic heart diseases) due to recurrent GAS infections, leading to high morbidity and mortality of young children and the elderly worldwide. Antibiotic drugs are the primary method of controlling and treating the early stages of GAS infection; however, the recent identification of clinical GAS isolates with reduced sensitivity to penicillin-adjunctive antibiotics and increasing macrolide resistance is an increasing threat. Vaccination is credited as the most successful medical intervention against infectious diseases since it was discovered by Edward Jenner in 1796. Immunisation with an inactive/live-attenuated whole pathogen or selective pathogen-derived antigens induces a potent adaptive immunity and protection against infectious diseases. Although no GAS vaccines have been approved for the market following more than 100 years of GAS vaccine development, the understanding of GAS pathogenesis and transmission has significantly increased, providing detailed insight into the primary pathogenic proteins, and enhancing GAS vaccine design. This review highlights recent advances in GAS vaccine development, providing detailed data from preclinical and clinical studies across the globe for potential GAS vaccine candidates. Furthermore, the challenges and future perspectives on the development of GAS vaccines are also described

show abstract

Spatiotemporal trends in global burden of rheumatic heart disease and associated risk factors from 1990 to 2019

Cited by 8 publications

References 22 publications

Temporal Trends and Burden of Rheumatic Heart Disease in South Asia: A Comprehensive Analysis of Three Decades from Global Burden of Disease Study

Temporal Trends and Burden of Rheumatic Heart Disease in South Asia: A Comprehensive Analysis of Three Decades from Global Burden of Disease Study

The burden and trends of headache disorders among the population aged 15–39: a study from 1990 to 2019

Recent Scientific Advancements towards a Vaccine against Group A Streptococcus

Contact Info

Product

Resources

About